A safe and sensitive enterovirus A71 infection model based on human SCARB2 knock-in mice

Vaccine

Volumn 34, Issue 24, 2016, Pages 2729-2736

  Zhou, Shuya ^a   Liu, Qiang ^a   Wu, Xing ^a   Chen, Pan ^a   Wu, Xi ^a   Guo, Yanan ^b   Liu, Susu ^a   Liang, Zhenglun ^a   Fan, Changfa ^a   Wang, Youchun ^a  

^a NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^b Biocytogen Co Ltd   (China)

Author keywords

Bioluminescent imaging; Enterovirus A71 mouse model; HSCARB2 knockin; Pseudotype virus; Vaccine effect evaluation

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; FIREFLY LUCIFERASE; INACTIVATED VIRUS VACCINE; NEUTRALIZING ANTIBODY; INACTIVATED VACCINE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; SCARB2 PROTEIN, HUMAN; SCAVENGER RECEPTOR; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; HAND FOOT AND MOUTH DISEASE; HUMAN SCARB2 KNOCK IN MOUSE; IN VIVO STUDY; INFECTION PREVENTION; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; DISEASE MODEL; ENTEROVIRUS A; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; GENETICS; HUMAN; IMMUNOLOGY; LUMINESCENCE; MALE; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; ENTEROVIRUS A, HUMAN; FEMALE; GENE KNOCK-IN TECHNIQUES; HAND, FOOT AND MOUTH DISEASE; HUMANS; LUMINESCENT MEASUREMENTS; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MALE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTAGENESIS, INSERTIONAL; RECEPTORS, SCAVENGER; VACCINES, INACTIVATED; VIRAL LOAD; VIRAL VACCINES;

EID: 84964211669     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.04.029     Document Type: Article

References (31)

1. McMinn P.C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 2002, 26:91-107.
2. Lin M.T., Wang J.K., Lu F.L., Wu E.T., Yeh S.J., Lee W.L., et al. Heart rate variability monitoring in the detection of central nervous system complications in children with enterovirus infection. J Crit Care 2006, 21:280-286.
3. Solomon T., Lewthwaite P., Perera D., Cardosa M.J., McMinn P., Ooi M.H. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010, 10:778-790.
4. Qiu J. Enterovirus 71 infection: a new threat to global public health?. Lancet Neurol 2008, 7:868-869.
5. Zhu F.C., Meng F.Y., Li J.X., Li X.L., Mao Q.Y., Tao H., et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013, 381:2024-2032.
6. Zhu F., Xu W., Xia J., Liang Z., Liu Y., Zhang X., et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 2014, 370:818-828.
7. Li R., Liu L., Mo Z., Wang X., Xia J., Liang Z., et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 2014, 370:829-837.
8. Wu C.N., Lin Y.C., Fann C., Liao N.S., Shih S.R., Ho M.S. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001, 20:895-904.
9. Foo D.G., Alonso S., Phoon M.C., Ramachandran N.P., Chow V.T., Poh C.L. Identification of neutralizing linear epitopes from the VP1 capsid protein of enterovirus 71 using synthetic peptides. Virus Res 2007, 125:61-68.
10. Liu J.N., Wang W., Duo J.Y., Hao Y., Ma C.M., Li W.B., et al. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 2010, 28:7444-7451.
11. Hashimoto I., Hagiwara A. Pathogenicity of a poliomyelitis-like disease in monkeys infected orally with enterovirus 71: a model for human infection. Neuropathol Appl Neurobiol 1982, 8:149-156.
12. Liu L., Zhao H., Zhang Y., Wang J., Che Y., Dong C., et al. Neonatal rhesus monkey is a potential animal model for studying pathogenesis of EV71 infection. Virology 2011, 412:91-100.
13. Zhang Y., Cui W., Liu L., Wang J., Zhao H., Liao Y., et al. Pathogenesis study of enterovirus 71 infection in rhesus monkeys. Lab Invest 2011, 91:1337-1350.
14. Bek E.J., Hussain K.M., Phuektes P., Kok C.C., Gao Q., Cai F., et al. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine 2011, 29:4829-4838.
15. Ong K.C., Devi S., Cardosa M.J., Wong K.T. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol 2010, 84:661-665.
16. Yu C.K., Chen C.C., Chen C.L., Wang J.R., Liu C.C., Yan J.J., et al. Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 2000, 7:523-528.
17. Yamayoshi S., Yamashita Y., Li J., Hanagata N., Minowa T., Takemura T., et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 2009, 15:798-801.
18. Lin Y.W., Yu S.L., Shao H.Y., Lin H.Y., Liu C.C., Hsiao K.N., et al. Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS One 2013, 8:e57591.
19. Fujii K., Nagata N., Sato Y., Ong K.C., Wong K.T., Yamayoshi S., et al. Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc Natl Acad Sci U S A 2013, 110:14753-14758.
20. Chen P., Song Z., Qi Y., Feng X., Xu N., Sun Y., et al. Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2. J Biol Chem 2012, 287:6406-6420.
21. Osorio J.E., Iams K.P., Meteyer C.U., Rocke T.E. Comparison of monkeypox viruses pathogenesis in mice by in vivo imaging. PLoS One 2009, 4:e6592.
22. Zaitseva M., Kapnick S.M., Scott J., King L.R., Manischewitz J., Sirota L., et al. Application of bioluminescence imaging to the prediction of lethality in vaccinia virus-infected mice. J Virol 2009, 83:10437-10447.
23. Liang Z., Mao Q., Gao Q., Li X., Dong C., Yu X., et al. Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine 2011, 29:9668-9674.
24. Wu X., Mao Q., Yao X., Chen P., Chen X., Shao J., et al. Development and evaluation of a pseudovirus-luciferase assay for rapid and quantitative detection of neutralizing antibodies against enterovirus 71. PLoS One 2013, 8:e64116.
25. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 1999, 21:70-71.
26. Madisen L., Zwingman T.A., Sunkin S.M., Oh S.W., Zariwala H.A., Gu H., et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat Neurosci 2010, 13:133-140.
27. Szymczak A.L., Workman C.J., Wang Y., Vignali K.M., Dilioglou S., Vanin E.F., et al. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 2004, 22:589-594.
28. Chong P., Liu C.C., Chow Y.H., Chou A.H., Klein M. Review of enterovirus 71 vaccines. Clin Infect Dis 2015, 60:797-803.
29. Huang C.C., Liu C.C., Chang Y.C., Chen C.Y., Wang S.T., Yeh T.F. Neurologic complications in children with enterovirus 71 infection. N Engl J Med 1999, 341:936-942.
30. Wang Y.F., Yu C.K. Animal models of enterovirus 71 infection: applications and limitations. J Biomed Sci 2014, 21:31.
31. Yamayoshi S., Ohka S., Fujii K., Koike S. Functional comparison of SCARB2 and PSGL1 as receptors for enterovirus 71. J Virol 2013, 87:3335-3347.